Journal Article Summary
The article investigates the trends in the use of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel among ischemic stroke patients who do not qualify for specific clinical trials, namely the CHANCE and POINT trials. This topic is significant because while DAPT has been shown to be beneficial for certain stroke patients, many individuals with more severe strokes or those who present late do not meet the criteria for these trials. Understanding how treatment practices have evolved over time can help identify gaps in care and inform future clinical guidelines.
The study analyzed data from over 32,000 patients admitted to 18 hospitals in South Korea between 2008 and 2022. Researchers found that the use of DAPT among patients ineligible for the CHANCE and POINT trials increased significantly after the publication of the CHANCE trial in 2013, rising from 33% in 2008 to 78% in 2022. Additionally, there was a noted improvement in the management of risk factors, such as the use of statins and diabetes medications, which may contribute to better outcomes for these patients.
However, the study has limitations, including a lack of data on the duration of DAPT use and potential confounding factors that could affect outcomes. Patients who received reperfusion therapy were excluded, which may limit the applicability of the findings. Readers should discuss with their healthcare providers the appropriateness of DAPT for their specific situation, especially if they have had a stroke that does not meet the typical trial criteria, as the benefits and risks of treatment can vary widely among individuals.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Kim Joon‐Tae, Lee Ji Sung, Kim Hyunsoo, Kim Beom Joon, Lee Keon‐Joo, Park Jong‐Moo, Kang Kyusik, Lee Soo Joo, et al.. Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2024. DOI: 10.1161/JAHA.123.033611. PMID: 38761083. PMCID: PMC11179811.
Featured Pill Pals Product
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs --- Over The Counter
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over — Generic For Bayer Low Dose — Time Cap Labs — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
